Drug Development

DNA repair mechanisms are activated by cytotoxic drugs either through specific lesion-driven mechanisms or activation of signaling pathways that constitute the DNA Damage Response (DDR). Enhanced repair of drug-induced DNA lesions has been associated to cellular resistance to various chemotherapeutic drugs. Conversely defects in DNA repair pathways would favor tumor sensitivity to DNA-damaging agents.

Decipher mechanisms of action to be more efficient

Because of the complexity and redundancy of DNA Repair mechanisms, the comprehensive, multiplexed and functional LXRepair test approach is an effective strategy to gain insight into the mechanisms of action of anti-cancer drugs (DNA damaging agents, DDR targeting drugs) and to validate combination therapies.
Regarding DNA Repair inhibitors, LXRepair tests measure their ability to affect DNA repair and bring information about their specificity and spectrum of action using pre-clinical and clinical models.

Specific DNA Repair Enzyme Signatures that correlate with the tumor ability to sense and respond to drugs can be associated to specific molecular profiles allowing identification of critical molecular pathways that drive the drug effect.


For additional information or to discuss partnership,
do not hesitate to contact us at
This email address is being protected from spambots. You need JavaScript enabled to view it.